- Home
- INMB vs SER Comparison
INMB vs SER Comparison
Compare INMB & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- SER
- Stock Information
- Founded
- INMB 2015
- SER 2017
- Country
- INMB United States
- SER United States
- Employees
- INMB N/A
- SER N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- SER Biotechnology: Pharmaceutical Preparations
- Sector
- INMB Health Care
- SER Health Care
- Exchange
- INMB Nasdaq
- SER Nasdaq
- Market Cap
- INMB 55.0M
- SER 55.2M
- IPO Year
- INMB 2019
- SER 2018
- Fundamental
- Price
- INMB $1.98
- SER $5.39
- Analyst Decision
- INMB Buy
- SER Strong Buy
- Analyst Count
- INMB 4
- SER 2
- Target Price
- INMB $9.53
- SER $13.00
- AVG Volume (30 Days)
- INMB 564.4K
- SER 24.9K
- Earning Date
- INMB 10-30-2025
- SER 11-11-2025
- Dividend Yield
- INMB N/A
- SER N/A
- EPS Growth
- INMB N/A
- SER N/A
- EPS
- INMB N/A
- SER N/A
- Revenue
- INMB $50,000.00
- SER $130,000.00
- Revenue This Year
- INMB $142.83
- SER $17.23
- Revenue Next Year
- INMB $14,780.90
- SER N/A
- P/E Ratio
- INMB N/A
- SER N/A
- Revenue Growth
- INMB N/A
- SER N/A
- 52 Week Low
- INMB $1.71
- SER $3.81
- 52 Week High
- INMB $11.64
- SER $8.14
- Technical
- Relative Strength Index (RSI)
- INMB 41.99
- SER 55.25
- Support Level
- INMB $1.92
- SER $5.09
- Resistance Level
- INMB $2.16
- SER $5.49
- Average True Range (ATR)
- INMB 0.11
- SER 0.25
- MACD
- INMB 0.03
- SER 0.05
- Stochastic Oscillator
- INMB 42.86
- SER 83.84
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.